2017 - CIRTA


This page contains exclusive content for the member of the following sections: TTS, ITA. Log in to view.

8- Immunological Monitoring, Rejection, and Mechanisms of Regeneration

36.3 - Vedolizumab for the Treatment of Refractory Severe Rejection in Intestinal Transplantation

Presenter: Thiago, Beduschi, Miami, United States
Authors: Thiago Beduschi, Jennifer Garcia, Jennifer Jebrock, Akin Tekin, Gennaro Selvaggi, Ji Fan, Seigo Nishida, Phillip Ruiz, Rodrigo Vianna

Vedolizumab for the Treatment of Refractory Severe Rejection in Intestinal Transplantation

Thiago Beduschi1, Jennifer Garcia1, Jennifer Jebrock1, Akin Tekin1, Gennaro Selvaggi1, Ji Fan1, Seigo Nishida1, Phillip Ruiz1, Rodrigo Vianna1.

1Miami Transplant Institute, University of Miami/ Jackson Memorial Hospital, Miami, FL, United States

Introduction: Acute cellular rejection (ACR) is a continuous challenge in intestinal transplantation despite the advent of potent immunosuppressive drugs. Most of the traditional drugs used to treat ACR destroy specific cell lines with important systemic side effects. Migration of the activated recipient lymphocytes (T Cells) to the mucosal surface can trigger ACR in intestinal transplant. It has been demonstrated in a murine model of intestinal transplantation that during ACR allografts are infiltrate by large numbers of α4β7 T cells and the treatment with a blocking antibody specific for β7 significantly reduces the cellular infiltrate and inhibits ACR[1]. Vedolizumab is a humanized monoclonal antibody that binds specifically to the α4β7 integrin, inhibiting T lymphocytes from binding to adhesion molecules (MAdCAM-1), which are expressed mainly in the small bowel and colon. Consequently, vedolizumab can be considered a specific intestinal immunosuppressant, making it especially attractive in intestinal transplantion. Vedolizumab could provide specific down-modulation of the mucosal inflammatory response that is characteristic of IBD and allograft intestinal rejection, thereby allowing re-establishment of homeostasis in the intestinal immune system.

Methods: Our group is reporting, to the best of our knowledge, the first report of using Vedolizumab for the treatment of severe ACR in intestinal transplantation.

Results: 25 years old, female, with history of Crohn’s disease received an intestinal and colon transplant. After 6 months of follow up patient started missing clinical appointments and presenting undetectable immunosuppressant levels. Eleven months after the transplant patient presented to the ER critically ill. Scope with biopsy was performed showing severely inflamed mucosa, absence of villi, diffuse bleeding and ulcers. All the viral studies were negative. Alemtuzumab 30 mg X 2, Rituximab and steroids were given. After 2 weeks without improvement of symptoms another endoscopic evaluation was performed. Areas of moderate to severe erythematous mucosa without villi, severe friability and active bleeding was found. Patient was over-immunosuppressed and we opted to treat with Vedolizumab (x3). After 10 days from the first dose, a new scope was performed showing regeneration of villi, improved friability and no active bleeding.  New scopes showed continuosly improvement of the mucosa followed by resolution of symptoms. PN was weaned and patient was discharged without parenteral support.

Conclusions: Vedolizumab was successfully used to rescue a patient with severe rejection after failure of other therapies. It acts specifically in the intestinal mucosa with a much safer side-effect profile. More studies are necessary but it may become an excellent choice to treat or prevent rejection in intestinal transplantation. 

[1] 1. Kellersmann R, et al. Monoclonal antibody against beta7 integrins, but not beta7 deficiency, attenuates intestinal allograft rejection in mice. Transplantation 2002 Nov 15;74(9):1327-34


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada